Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) just unveiled an update.
Hemogenyx Pharmaceuticals has secured £451,250 to continue its Phase 1 clinical trials for its Chimeric Antigen Receptor T-cell therapy, HG-CT-1, aimed at treating relapsed/refractory acute myeloid leukemia in adults. The funding, raised through an allotment of new ordinary shares to CEO Vladislav Sandler, reflects investor confidence in the company’s long-term value and supports the momentum of its clinical development without diluting shareholder value.
More about HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals plc is a clinical stage biopharmaceutical company based in London, with US subsidiaries in New York City. The company focuses on developing new medicines and treatments for blood and autoimmune diseases, utilizing distinct product candidates and platform technologies for novel product development.
Average Trading Volume: 38,023
Technical Sentiment Signal: Sell
Current Market Cap: £7.52M
Find detailed analytics on HEMO stock on TipRanks’ Stock Analysis page.